PECO Pallet Announces Acquisition by The Pritzker Group
22.2.2011 19:40:25 CET | Business Wire | Press release
PECO Pallet Inc. announced today that the company has been acquired by The Pritzker Group, a private investment firm owned and controlled by J.B. Pritzker and Tony Pritzker. The acquisition provides PECO Pallet with substantial equity capital to fund the company’s continued expansion throughout the U.S., Canada, and Mexico. Terms of the deal were not disclosed.
The Pritzkers’ acquisition follows more than five years of significant growth for PECO Pallet, whose exceptional pallet quality, operational performance and service support have made the company a North American leader in pallet rental services. PECO’s signature red wood block pallets are used by an increasing number of market leaders in the consumer packaged goods industries and over 95% of top U.S. retailers. Customers who have tried other pallet pooling options, as well as those switching from whitewood pallets, have embraced the PECO Pallet rental model for its simplicity and overall value.
“PECO Pallet’s world-class customer service and leading edge logistics systems made the company a perfect fit for us,” said J.B. Pritzker, Managing Partner of The Pritzker Group. “Over the last several years, PECO’s management team has delivered a growth trajectory that has established the company as an industry leader. Our investment of new growth capital, plus the capital available under a new and substantially larger credit facility, will help drive key initiatives and accelerate PECO Pallet’s penetration of the rental market.”
David Lee, CEO of PECO Pallet, added, “PECO Pallet’s acquisition by The Pritzker Group will enable our company to continue expanding throughout North America. We have a great deal of respect for the Pritzkers and their team, who have an excellent reputation as high integrity, value-added, long-term partners. Together, we remain committed to maintaining PECO’s ‘best-in-class’ pallet pool and exceptional customer service.”
The transaction is subject to customary closing conditions and anticipated to close by the end of the first quarter of 2011.
About PECO Pallet:
PECO Pallet is a North American leader in pallet rental services. Over 95% of U.S. grocery, warehouse, club and discount retailers currently utilize PECO’s signature red block pallets. PECO Pallet’s tremendous growth over the last decade reflects the company’s overall commitment to exceptional quality and genuine passion for customer service excellence. PECO is headquartered in New York and maintains over 300 service centers and manufacturing plants throughout the U.S., Canada, and Mexico. For more information about PECO Pallet, visit www.pecopallet.com .
About The Pritzker Group:
The Pritzker Group is a private investment firm representing Pritzker family interests. Its reputation is built on strong management partnerships and a focus on excellence. Led by Tony Pritzker and J.B. Pritzker, the firm has completed more than 50 transactions, focusing on high-quality, mature, and profitable businesses with value-added products and services, stable-to-high growth profiles, and strong market positions. For more information, please visit www.pritzkergroup.com .
Contact:
PECO Pallet, Inc.
Tom Kuczmarski, 914-376-5185 (CFO)
tkuczmarski@pecopallet.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom